URGNUroGen PharmaURGN info
$11.33info0.27%24h
Global rank13780
Market cap$349.72M
Change 7d0.27%
YTD Performance-24.32%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    UroGen Pharma (URGN) Stock Overview

    UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

    URGN Stock Information

    Symbol
    URGN
    Address
    400 Alexander ParkPrinceton, NJ 08540United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.urogen.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    646 768 9780

    UroGen Pharma (URGN) Price Chart

    -
    Value:-

    UroGen Pharma Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $11.33
    N/A
    Market Cap
    $349.72M
    N/A
    Shares Outstanding
    30.87M
    N/A
    Employees
    192.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org